Stefani Spranger is an Associate Professor of Biology at MIT. She received her bachelor's and master's degrees from the Ludwig-Maximilians University in Munich. She received her PhD in 2011 from the Helmholtz-Zentrum Munich, Institute for Molecular Immunology, where she conducted her doctoral work under the supervision of Professor Dolores J. Schendel. Spranger completed her postdoctoral training at the University of Chicago in the laboratory of Professor Thomas F. Gajewski. During this period, she was supported by a German Research Foundation postdoctoral fellowship and subsequently received the Cancer Research Institute's Irvington Postdoctoral Fellowship. Dr. Spranger is a Scholar of the William Guy Forbeck Research Foundation and is a Pew-Stewart Scholar for Cancer Research. She was elected to the Board of Directors of the Society for Immunotherapy of Cancer in 2019.

Dr. Spranger is a co-founder of Danger Bio. She is a member of the Scientific Advisory Board of Arcus Biosciences, Danger Bio and Prox Bio. In addition, she acts as advisor to Dragonfly, Merck, Abbvie and Takeda. Her group receives research funding from Leap Therapeutics.